STTK vs OIG Comparison

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Orion180 Insurance Group Inc operating as an insurance holding company. It is a founder-led, technology-focused, high-growth, high-margin specialty insurance group delivering insurance solutions with a growing footprint across the United States. The group operates in two segments: Services and Underwriting. The Services segment includes technology-enabled policy servicing operations, including intercompany revenue earned through service arrangements between the Services and Underwriting segments. The Underwriting segment includes a conventional, regulated insurance model focused on risk selection, pricing, and statutory capital management. The segment also includes a segregated cell designed to assume reinsurance risk.